• OPEN AN ACCOUNT
Indian Indices
Sensex
74,654.21 -204.78
( -0.27%)
Global Indices
Nasdaq
52,073.35 369.71
(0.72%)
Dow Jones
7,785.28 113.78
(1.48%)
Hang Seng
65,040.24 903.99
(1.41%)
Nikkei 225
10,737.46 78.33
(0.73%)
Forex
USD-INR
95.99 0.12
(0.12%)
EUR-INR
110.24 0.24
(0.22%)
GBP-INR
128.54 0.36
(0.28%)
JPY-INR
0.61 0.00
(-0.53%)

EQUITY - MARKET SCREENER

Maruti Suzuki India Ltd
Industry :  Automobiles - Passenger Cars
BSE Code
ISIN Demat
Book Value()
532500
INE585B01010
3343.1596933
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
MARUTI
27.26
382690.81
EPS(TTM)
Face Value()
Div & Yield %
446.54
5
1.15
 

Lupin receives USFDA approval for Modafinil Tablets USP
Sep 04,2026
Lupin has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Modafinil Tablets USP, 100 mg and 200 mg.

The U.S. FDA has approved Lupin's Modafinil Tablets USP, 100 mg and 200 mg as bioequivalent to the reference listed drug (RLD), Provigil® Tablets of Nuvo Pharmaceuticals (Ireland) DAC, and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA) or shift work disorder (SWD).

Modafinil Tablets (RLD Provigil®) had estimated annual sales of USD 70.7 million in the U.S. (IQVIA MAT Jul 2026).